Literature DB >> 28962206

Overexpression of CD147 is associated with poor prognosis, tumor cell migration and ERK signaling pathway activation in hepatocellular carcinoma.

Wenjing Xiao1, Shufen Zhao1, Fangzhen Shen1, Jun Liang1, Jing Chen1.   

Abstract

Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide. The aim of the present study was to reveal the prognostic significance of CD147 and to preliminarily explore the molecular mechanisms involved. Blood and tumor tissue specimens were obtained from 133 HCC patients. All patients were followed up for 4 years. The serum and tissue levels of CD147 were analyzed using ELISA and immunohistochemistry, respectively. The SMMC-7721 hepatoma carcinoma cell line was transfected with CD147 overexpression vector and cell migration was evaluated using a wound healing assay. Extracellular signal-regulated kinase (ERK) inhibitor UO126 was applied to study the role of the ERK pathway in cell migration. CD147 expression in HCC tissue was associated with poor prognosis of patients [odds ratio (OR): 3.13, 95% confidence interval (CI): 1.52-6.43], and patients with no CD147 expression had a significantly survival advantage (P=0.016). However, serum CD147 levels had no such prognostic significance (OR: 1.94, 95% CI: 0.96-3.91; P=0.097). In the wound healing assay, the wound distance in the non-transfected cell group was wider than that in the transfected cell group without UO126 treatment (178.0±31.1 vs. 106.0±20.7 µm; P=0.003), but similar to that in the transfected cell group with 10 µM UO126 treatment (170.4±13.2 µm; P=0.629). The present study revealed that the expression of CD147 in HCC tissue is an independent prognostic indicator. In addition CD147 overexpression may be associated with tumor cell migration and ERK signaling pathway activation.

Entities:  

Keywords:  CD147; ERK signaling pathway; hepatocellular carcinoma; migration; prognosis

Year:  2017        PMID: 28962206      PMCID: PMC5609212          DOI: 10.3892/etm.2017.4818

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  30 in total

1.  A new method for quantitative analysis of cell surface glycoproteome.

Authors:  Zhen Sun; Rui Chen; Kai Cheng; Hongwei Liu; Hongqiang Qin; Mingliang Ye; Hanfa Zou
Journal:  Proteomics       Date:  2012-10-29       Impact factor: 3.984

2.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

3.  HAb18G/CD147 promotes epithelial-mesenchymal transition through TGF-β signaling and is transcriptionally regulated by Slug.

Authors:  J Wu; N-Y Ru; Y Zhang; Y Li; D Wei; Z Ren; X-F Huang; Z-N Chen; H Bian
Journal:  Oncogene       Date:  2011-05-02       Impact factor: 9.867

4.  CD147 and AGR2 expression promote cellular proliferation and metastasis of head and neck squamous cell carcinoma.

Authors:  Larissa Sweeny; Zhiyong Liu; Benjamin D Bush; Yolanda Hartman; Tong Zhou; Eben L Rosenthal
Journal:  Exp Cell Res       Date:  2012-05-30       Impact factor: 3.905

Review 5.  Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma.

Authors:  Mary Maluccio; Anne Covey
Journal:  CA Cancer J Clin       Date:  2012-10-15       Impact factor: 508.702

6.  [Significance and application of anti-malignant hepatoma MAb HAb18 in radioimmunal diagnosis of human hepatocellular carcinoma].

Authors:  Z N Chen
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  1992-01

7.  HAb18G (CD147), a cancer-associated biomarker and its role in cancer detection.

Authors:  Yu Li; Jing Xu; Ling Chen; Li Chen; Wei-De Zhong; Zheng Zhang; Li Mi; Yang Zhang; Cheng-Gong Liao; Hui-Jie Bian; Jian-Li Jiang; Xiang-Min Yang; Xiao-Yan Li; Chun-Mei Fan; Ping Zhu; Li Fu; Zhi-Nan Chen
Journal:  Histopathology       Date:  2009-05       Impact factor: 5.087

8.  Downregulation of CD147 expression by RNA interference inhibits HT29 cell proliferation, invasion and tumorigenicity in vitro and in vivo.

Authors:  Rui Li; Yuqin Pan; Bangshun He; Yeqiong Xu; Tianyi Gao; Guoqi Song; Huiling Sun; Qiwen Deng; Shukui Wang
Journal:  Int J Oncol       Date:  2013-09-23       Impact factor: 5.650

9.  Prognostic value of serum AFP, AFP-L3, and GP73 in monitoring short-term treatment response and recurrence of hepatocellular carcinoma after radiofrequency ablation.

Authors:  Nan-Ya Wang; Cong Wang; Wei Li; Guan-Jun Wang; Guo-Zhen Cui; Hua He; Heng-Jun Zhao
Journal:  Asian Pac J Cancer Prev       Date:  2014

10.  EMMPRIN promotes angiogenesis, proliferation, invasion and resistance to sunitinib in renal cell carcinoma, and its level predicts patient outcome.

Authors:  Mototaka Sato; Yasutomo Nakai; Wataru Nakata; Takahiro Yoshida; Koji Hatano; Atsunari Kawashima; Kazutoshi Fujita; Motohide Uemura; Hitoshi Takayama; Norio Nonomura
Journal:  PLoS One       Date:  2013-09-20       Impact factor: 3.240

View more
  6 in total

1.  Dual effects of an anti-CD147 antibody for Esophageal cancer therapy.

Authors:  Miao Wang; Shuai Zhang; Qian Sun; Xiangmin Yang; Yu Wang; Runze Shang; Yumeng Zhu; Hui Yao; Yu Li
Journal:  Cancer Biol Ther       Date:  2019-08-14       Impact factor: 4.742

Review 2.  Novel antigens for targeted radioimmunotherapy in hepatocellular carcinoma.

Authors:  Mahsa Pourhamzeh; Samieh Asadian; Hamed Mirzaei; Azita Minaei; Elahe Shahriari; Anastasia Shpichka; Hamidreza Aboulkheyr Es; Peter Timashev; Moustapha Hassan; Massoud Vosough
Journal:  Mol Cell Biochem       Date:  2022-06-16       Impact factor: 3.396

3.  Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma.

Authors:  Hsiang-Chi Tseng; Wei Xiong; Saiaditya Badeti; Yan Yang; Minh Ma; Ting Liu; Carlos A Ramos; Gianpietro Dotti; Luke Fritzky; Jie-Gen Jiang; Qing Yi; James Guarrera; Wei-Xing Zong; Chen Liu; Dongfang Liu
Journal:  Nat Commun       Date:  2020-09-23       Impact factor: 17.694

4.  Discovery and Biological Evaluation of CD147 N-Glycan Inhibitors: A New Direction in the Treatment of Tumor Metastasis.

Authors:  Wenqian Li; Daojiong Wang; Yushu Ge; Lei Zhang; Jiang Wu; Dan Liu
Journal:  Molecules       Date:  2020-12-23       Impact factor: 4.411

Review 5.  Novel Nanotechnology Approaches to Overcome Drug Resistance in the Treatment of Hepatocellular Carcinoma: Glypican 3 as a Useful Target for Innovative Therapies.

Authors:  Monica Mossenta; Davide Busato; Michele Dal Bo; Paolo Macor; Giuseppe Toffoli
Journal:  Int J Mol Sci       Date:  2022-09-02       Impact factor: 6.208

6.  Discovery and validation of surface N-glycoproteins in MM cell lines and patient samples uncovers immunotherapy targets.

Authors:  Robyn A A Oldham; Mary L Faber; Theodore R Keppel; Amanda R Buchberger; Matthew Waas; Parameswaran Hari; Rebekah L Gundry; Jeffrey A Medin
Journal:  J Immunother Cancer       Date:  2020-08       Impact factor: 13.751

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.